Breast Cancer Research and Treatment

, Volume 2, Issue 4, pp 331–337 | Cite as

Tumor-associated prostaglandins in patients with primary breast cancer: Relationship to clinical parameters

  • Amy Fulton
  • Larry Roi
  • Laura Howard
  • Jose Russo
  • Samuel Brooks
  • Michael J. Brennan


Determination of the levels of prostaglandin E2 (PGE2) and PGF were carried out using homogenized primary human breast tumors. Measurable levels of both prostaglandins were found in all but one tumor examined. In most samples, the absolute PGF level was higher than that of PGE2. Higher PGE2 levels are more often seen in postmenopausal women than in pre- or perimenopausal patients, though among postmenopausal women, PGE2 levels do not correlate with age. Thus, the ratio of PGF:PGE is higher in pre/perimenopausal women than in postmenopausal women. Differences in PGF do not appear to be associated with age or menopausal status.

Tumors that are estrogen receptor positive (ER +) tend to have higher PGE2 levels than ER negative tumors. PGF is not associated with the presence of ER and neither prostaglandin is associated with the presence of progesterone receptor. Higher levels of both PGE2 and PGF are associated with less differentiated tumors, while tumor maximum diameter is negatively associated with PGE2 levels.


breast cancer clinical correlates prostaglandins 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rolland PH, Martin PM, Jacquemier J, Rolland AM, Toga M: Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 64: 1061–1070, 1980.Google Scholar
  2. 2.
    Powles TJ, Dowsett M, Easty GC, Easty DM, Neville AM: Breast cancer osteolysis, bone metastases and anti-osteolytic effect of aspirin. Lancet i: 608–610, 1976.Google Scholar
  3. 3.
    Dady PJ, Powles TJ, Dowsett M, Easty G, Williams J, Neville AM: In vitro osteolytic activity of human breast carcinoma tissue and prognosis. Br J Cancer 43: 222–225, 1981.Google Scholar
  4. 4.
    Bennett A, Charlier EM, McDonald AM, Simpson JS, Stamford IF: Prostaglandins and breast cancer. Lancet ii: 624–626, 1977.Google Scholar
  5. 5.
    Bennett A, Berstock DA, Raja B, Stamford IF: Survival time after surgery is inversely related to the amounts of prostaglandins extracted from human breast cancers. Br J Pharmacol 66: 451, 1979.Google Scholar
  6. 6.
    Singhakowinta A, Potter HG, Buroker TR, Samal B, Brooks SC, Vaitkevicius VK: Estrogen receptor and natural course of breast cancer. Ann Surg 183: 84–88, 1976.Google Scholar
  7. 7.
    Brooks SC, Saunders DE, Singhakowinta A, Vaitkevicius VK: Relation of tumor content of estrogen and progesterone receptors with response of patient to endocrine therapy. Cancer 46: 2775–2781, 1980.Google Scholar
  8. 8.
    Rich MA, Brennan MJ, the scientific, pathology and surgical associates of the Michigan Cancer Foundation: The Breast Cancer Prognostic Program: A study of the metastatic process.In MJ Brennan, CC McGrath, and MA Rich (eds). Breast Cancer: New Concepts in Etiology and Control. Academic Press, New York, 1980, pp 29–54.Google Scholar
  9. 9.
    Bloom HJG, Richardson WW: Histologic grading and prognosis in breast cancer: A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359–377, 1957.Google Scholar
  10. 10.
    Black MM, Opler SR, Speer FD: Survival in breast cancer cases in relation to the structure of the primary tumor and regional lymph nodes. Surg Gynecol Obstet 100: 543–551, 1955.Google Scholar
  11. 11.
    Black MM, Speer FD: Nuclear structure in cancer tissues. Surg Gynecol Obstet 105: 97–102, 1957.Google Scholar
  12. 12.
    Black MM, Speer FD, Opler SR: Structural representations of tumor-host relationships in mammary carcinoma. Biologic and prognostic significance. Am J Clin Pathol 26: 250–265, 1956.Google Scholar
  13. 13.
    Foote FW Jr: Surgical pathology of cancer of the breast.In WH Parsons (ed). Cancer of the Breast. Charles C. Thomas, Springfield, 1959, pp 37–38.Google Scholar
  14. 14.
    Mood AM, Graybill FA: Introduction to the Theory of Statistics, McGraw-Hill, New York, 1963, p 312.Google Scholar
  15. 15.
    Rolland PH, Martin PM, Jacquemier J, Rolland AM, Toga M: Prostaglandin production and metabolism in human breast cancer.In B Samuellson, PW Ramwell, and R Paoletti (eds). Advances in Prostaglandin and Thromboxane Research, Vol. 6. Raven Press, New York, 1980, pp 575–580.Google Scholar
  16. 16.
    Kibbey WE, Bronn DG, Minton JP: Prostaglandin synthetase and prostaglandin E2 in human breast carcinoma. Prostag Medicine 2: 133–139, 1979.Google Scholar
  17. 17.
    Hammerstrom S: Endogenous prostaglandin production and cell replication in vitro.In TJ Powles, RS Bockman, KV Honn, and P Ramwell (eds). Prostaglandins and Cancer. AR Liss Inc, New York, 1982, pp 297–308.Google Scholar
  18. 18.
    Gunasegaram R, Loganath A, Peh KL, Chiang SC, Ratnam SS: Identification of prostaglandins in infiltrating duct carcinoma of the human breast. IRCS Med Sci 8: 747–748, 1981.Google Scholar
  19. 19.
    Malachi T, Chaimoff C, Feller N, Halbrecht I: Prostaglandin E2 and cyclic AMP in tumor and plasma of breast cancer patients. J Cancer Res Clin Oncol 102: 71–79, 1981.Google Scholar
  20. 20.
    Rolland PH, Martin PM: Opposite effects of estrogens and anti-estrogens on prostaglandin synthetase from human breast cancer (meeting abstract).In TJ Powles, RS Bockman, KV Honn, and P Ramwell (eds). Prostaglandins and Cancer. AR Liss, Inc, New York.Google Scholar
  21. 21.
    Knacek RA, Watson KC, Lim MG, Cannizzaro AM, Christy RJ, Liu SC: Prostaglandin synthesis by murine mammary gland is modified by the state of the estrus cycle. Prostaglandins 19: 891–897, 1980.Google Scholar
  22. 22.
    Kenimer JG, Goldberg V, Belcher M:In PW Ramwell (ed). The Prostaglandins. Plenum Press, New York, 1977, pp 77–82.Google Scholar
  23. 23.
    Powles TJ, Clark SA, Easty DM, Easty GC, Neville AM: The inhibition by aspirin and indomethacin of osteolytic tumor deposits and hypercalcemia in rats with Walker tumor and its possible application to human breast cancer. Br J Cancer 28: 316–321, 1973.Google Scholar
  24. 24.
    Humes JR, Strausser HR: Prostaglandins and cyclic nucleotides in Moloney sarcoma tumors. Prostaglandins 5: 183–196, 1974.Google Scholar
  25. 25.
    Plescia OJ, Smith AH, Grinwich K: Subversion of immune system by tumor cells and role of prostaglandins. Proc Natl Acad Sci USA 72: 1848–1851, 1975.Google Scholar
  26. 26.
    Strausser HR, Humes JL: Prostaglandin synthesis inhibition: Effect on bone changes and sarcoma tumor induction in BALB/c mice. Int J Cancer 15: 724–730, 1975.Google Scholar
  27. 27.
    Fulton AM, Levy JG: The possible role of prostaglandins in mediating immune suppression by nonspecific T suppressor cells. Cell Immunol 52: 29–37, 1980.Google Scholar
  28. 28.
    Powles TJ, Dady PJ, Williams J, Easty GC, Coombes RC: Use of inhibitors of prostaglandin synthesis in patients with breast cancer.In B Samuellson, PW Ramwell, and R Paoletti (eds). Advances in Prostaglandin and Thromboxane Research, Vol 6. Raven Press, New York, 1980, pp 511–516.Google Scholar
  29. 29.
    Fulton AM: Prostaglandin levels in mammary tumors of varying malignant potential (Abstract). Proc AACR 22: 61, 1981.Google Scholar
  30. 30.
    Fulton A, Rios A, Loveless S, Heppner G: Prostaglandins in tumor-associated cells.In TJ Powles, RS Bockman, KV Honn, and P Ramwell (eds). Prostaglandins and Cancer. AR Liss, Inc, New York, 1982, pp 701–703.Google Scholar

Copyright information

© Martinus Nijhoff Publishers 1982

Authors and Affiliations

  • Amy Fulton
    • 1
  • Larry Roi
    • 1
  • Laura Howard
    • 1
  • Jose Russo
    • 1
  • Samuel Brooks
    • 2
  • Michael J. Brennan
    • 1
  1. 1.Michigan Cancer FoundationDetroitUSA
  2. 2.Wayne State UniversityDetroitUSA

Personalised recommendations